Study details
Enrolling now
A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives
AbbVie
NCT IDNCT07414784ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Ages
18–65
Sex
Female only
Locations
1 site in IL
What this study is about
This Phase 1 study is testing Ethinyl Estradiol in people with healthy volunteers. The primary outcome being measured is Number of Participants with Adverse Events (AEs).
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
OralOral
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
ethinylestradiol, progestin (hormonal contraceptive)
Drug routes
oral (Oral Tablet)
Endpoints
Primary: Number of Participants with Adverse Events (AEs)